The first-in-class mAb to target MM was Daratumumab, an anti-CD38 mAb which was shown to facilitate lysis of MM plasma cells through various antibody-mediated mechanisms such as ADCC, CDC, and ADCP, significantly improving the outcomes of patients with relapsed or refractory myeloma. Here, CD38 is linked to Miyoshi myopathy.